GBI Research has released its pharmaceutical research, “”Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat””, which provides insights into three cardiovascular therapeutic indications in the top eight markets of the US, the UK, Germany, France, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the cardiovascular therapeutic indications, namely heart failure, myocardial infarction (MI), acute coronary syndrome (ACS). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three cardiovascular indications.

Scope

• Disease overview and treatment usage patterns
• Market size and forecast for heart failure, Myocardial Infarction (MI) and Acute Coronary Syndrome (ACS)
• Geographic coverage includes the top eight markets (the US, the UK, Germany, France, Italy, Spain, Japan and Canada) from 2012 to 2019
• Major marketed products for the indications types covered
• In-depth pipeline analysis for heart failure, MI and ACS
• Key drivers and restraints that have had and are expected to have a significant impact upon the market
• Key licensing and co-development agreements in the cardiovascular market

Reasons to buy

• The report will enhance your decision-making capability by allowing you to
• Align your product portfolio to the markets with high growth potential
• Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
• Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the cardiovascular market
• Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
• Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Table of Contents

1 Table of Contents 5

1.1 List of Tables 8

1.2 List of Figures 9

2 Introduction 10

3 Therapeutic Landscape 11

3.1 Heart Failure 11

3.1.1 Symptoms 11

3.1.2 Etiology 12

3.1.3 Pathophysiology 12

3.1.4 Co-morbidities and Complications 12

3.1.5 Diagnosis 13

3.1.6 Classification 14

3.1.7 Prognosis and Disease Staging 14

3.1.8 Treatment Options 15

3.2 Myocardial Infarction 18

3.2.1 Symptoms 18

3.2.2 Etiology 18

3.2.3 Pathophysiology 18

3.2.4 Co-morbidities and Complications 19

3.2.5 Diagnosis 19

3.2.6 Classification 20

3.2.7 Treatment Options 21

3.3 Acute Coronary Syndrome 22

3.3.1 Symptoms 22

3.3.2 Etiology 22

3.3.3 Pathophysiology 23

3.3.4 Diagnosis 23

3.3.5 Treatment Options 24

4 Marketed Products 27

4.1 Heart Failure 27

4.2 Myocardial Infarction 27

4.3 Acute Coronary Syndrome 27

4.4 Key Marketed Products 27

4.4.1 Arixtra 27

4.4.2 Brilinta 29

4.4.3 Crestor 30

4.4.4 Diovan and Diovan HCT/Co-Diovan 31

4.4.5 Atacand 31

4.4.6 Lipitor 32

4.4.7 Clopidogrel bisulfate 33

4.4.8 Angiomax 33

4.4.9 Lovenox 34

4.4.10 Norvasc 35

4.4.11 Coreg 35

4.4.12 Ivabradine 37

4.4.13 Toprol-XL 37

5 Pipeline Analysis 39

5.1 Heart Failure Pipeline 39

5.1.1 Overall Pipeline 39

5.1.2 Pipeline Analysis by Molecule Type 40

5.1.3 Pipeline Analysis by Mechanism of Action 41

5.2 Myocardial Infarction Pipeline 42

5.2.1 Overall Pipeline 42

5.2.2 Pipeline Analysis by Molecule Type 43

5.2.3 Pipeline Analysis by Mechanism of Action 44

5.3 Acute Coronary Syndrome Pipeline 45

5.3.1 Overall Pipeline 45

5.3.2 Pipeline Analysis by Molecule Type 46

5.3.3 Pipeline Analysis by Mechanism of Action 47

5.4 Promising Drug Candidates in the Pipeline 48

5.4.1 LCZ-696 48

5.4.2 Darapladib (SB-480848) 49

5.4.3 Neucardin 50

5.4.4 Cangrelor 51

5.4.5 Serelaxin (Novartis AG) 51

6 Cardiovascular Diseases Global Market to 2019, Market Forecast 52

6.1 Global Market 52

6.1.1 Treatment Usage Patterns 52

6.1.2 Annual Cost of Treatment 52

6.1.3 Market Size 52

6.2 US 54

6.2.1 Treatment Usage Patterns 54

6.2.2 Annual Cost of Treatment 54

6.2.3 Market Size 54

6.3 France 56

6.3.1 Treatment Usage Patterns 56

6.3.2 Annual Cost of Treatment 56

6.3.3 Market Size 56

6.4 Spain 58

6.4.1 Treatment Usage Patterns 58

6.4.2 Annual Cost of Treatment 58

6.4.3 Market Size 58

6.5 Germany 60

6.5.1 Treatment Usage Patterns 60

6.5.2 Annual Cost of Treatment 60

6.5.3 Market Size 60

6.6 Italy 62

6.6.1 Treatment Usage Patterns 62

6.6.2 Annual Cost of Treatment 62

6.6.3 Market Size 62

6.7 UK 64

6.7.1 Treatment Usage Patterns 64

6.7.2 Annual Cost of Treatment 64

6.7.3 Market Size 64

6.8 Japan 66

6.8.1 Treatment Usage Patterns 66

6.8.2 Annual Cost of Therapy 66

6.8.3 Market Size 66

6.9 Canada 68

6.9.1 Treatment Usage Patterns 68

6.9.2 Annual Cost of Treatment 68

6.9.3 Market Size 68

6.10 Drivers and Barriers for the Global Cardiovascular Diseases Market 70

6.10.1 Drivers 70

6.10.2 Barriers 70

7 Deals and Strategic Consolidations 71

7.1 Deals Analysis 71

7.2 Major Co-development Deals 73

7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics 74

7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics 74

7.2.3 Cytokinetics Signs Strategic Agreement with Amgen 74

7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. 74

7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. 75

7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited 75

7.3 Major Licensing Deals 76

7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine 77

7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc. 77

7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. 77

7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb 77

7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck & Co., Inc. for Cardiovascular Therapeutic Candidates 78

7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. 79

7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck & Co, Inc. 79

7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics 79

8 Appendix 80

8.1 Market Definitions 80

8.2 Abbreviations 80

8.3 Sources 82

8.4 All Pipeline Drugs by Phase 84

8.4.1 Preclinical 84

8.4.2 Pre-registration 87

8.4.3 Phase I 88

8.4.4 Phase II 89

8.4.5 Phase III 91

8.4.6 Discontinued 92

8.4.7 Filing rejected/Withdrawn 93

8.5 Market Forecasts to 2019 93

8.5.1 Global 93

8.5.2 US 94

8.5.3 UK 95

8.5.4 France 96

8.5.5 Spain 97

8.5.6 Germany 98

8.5.7 Italy 99

8.5.8 Japan 100

8.5.9 Canada 101

8.6 Research Methodology 102

8.6.1 Coverage 102

8.6.2 Secondary Research 102

8.6.3 Primary Research 103

8.6.4 Therapeutic Landscape 103

8.6.5 Geographical Landscape 106

8.6.6 Pipeline Analysis 106

8.7 Expert Panel Validation 106

8.8 Contact Us 106

8.9 Disclaimer 106

List of Tables

Table 1: Cardiovascular Diseases Market Global, General Symptoms of Congestive Heart Failure by Stage, 2013 11

Table 2: Cardiovascular Market, Global, Pharmaceutical Pipeline (Preclinical), 2013 84

Table 3: Cardiovascular Market, Global, Pharmaceutical Pipeline (Pre-registration), 2013 87

Table 4: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase I), 2013 88

Table 5: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase II), 2013 89

Table 6: Cardiovascular Market, Global, Pharmaceutical Pipeline (Phase III), 2013 91

Table 7: Cardiovascular Market, Global, Pharmaceutical Pipeline (Discontinued), 2013 92

Table 8: Cardiovascular Market, Global, Pharmaceutical Pipeline (Filing rejected Withdrawn), 2013 93

Table 9: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Global, Market Forecast, 2012-2019 93

Table 10: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Global, Market Forecast, 2012-2019 93

Table 11: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Global, Market Forecast, 2012-2019 94

Table 12: Cardiovascular Diseases in Global Market to 2019, Heart Failure, US, Market Forecast, 2012-2019 94

Table 13: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, US, Market Forecast, 2012-2019 94

Table 14: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, US, Market Forecast, 2012-2019 95

Table 15: Cardiovascular Diseases in Global Market to 2019, Heart Failure, UK, Market Forecast, 2012-2019 95

Table 16: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, UK, Market Forecast, 2012-2019 95

Table 17: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, UK, Market Forecast, 2012-2019 96

Table 18: Cardiovascular Diseases in Global Market to 2019, Heart Failure, France, Market Forecast, 2012-2019 96

Table 19: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, France, Market Forecast, 2012-2019 96

Table 20: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, France, Market Forecast, 2012-2019 97

Table 21: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Spain, Market Forecast, 2012-2019 97

Table 22: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Spain, Market Forecast, 2012-2019 97

Table 23: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Spain, Market Forecast, 2012-2019 98

Table 24: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Germany, Market Forecast, 2012-2019 98

Table 25: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Germany, Market Forecast, 2012-2019 98

Table 26: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Germany, Market Forecast, 2012-2019 99

Table 27: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Italy, Market Forecast, 2012-2019 99

Table 28: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Italy, Market Forecast, 2012-2019 99

Table 29: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Italy, Market Forecast, 2012-2019 100

Table 30: Cardiovascular Diseases Market to 2019, Heart Failure, Japan, Market Forecast, 2012-2019 100

Table 31: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Japan, Market Forecast, 2012-2019 100

Table 32: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Japan, Market Forecast, 2012-2019 101

Table 33: Cardiovascular Diseases in Global Market to 2019, Heart Failure, Canada, Market Forecast, 2012-2019 101

Table 34: Cardiovascular Diseases in Global Market to 2019, Myocardial Infarction, Canada, Market Forecast, 2012-2019 101

Table 35: Cardiovascular Diseases in Global Market to 2019, Acute Coronary Syndrome, Canada, Market Forecast, 2012-2019 102

List of Figures

Figure 1: Cardiovascular Diseases Market, Global, Heart Failure Treatment Algorithm, 2013 17

Figure 2: Cardiovascular Diseases Market, Global, Subtypes of Myocardial Infarction by Clinical Scenario, 2013 20

Figure 3: Cardiovascular Diseases Market, Global, Acute Coronary Syndrome Treatment Algorithm, 2013 26

Figure 4: Cardiovascular Diseases Market , Arixtra, Global, Annual Sales ($m), 2009-2012 28

Figure 5: Cardiovascular Diseases Market, Brilinta, Global, Annual Sales ($m), 2011-2012 29

Figure 6: Cardiovascular Diseases Market, Crestor, Global, Annual Sales ($m), 2009-2012 30

Figure 7: Cardiovascular Diseases Market to 2019, Lovenox, Global, Annual Sales ($m), 2009-2012 34

Figure 8: Cardiovascular Diseases Market, Coreg, Global, Annual Sales ($m), 2006-2012 36

Figure 9: Cardiovascular Diseases Market to 2019, Toprol-XL, Global, Annual Sales ($m), 2007-2012 38

Figure 10: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline, 2012 39

Figure 11: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Molecule Type, 2012 40

Figure 12: Cardiovascular Diseases Market to 2019, Heart Failure, Global, Pipeline by Mechanism of Action, 2012 41

Figure 13: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline, 2012 42

Figure 14: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Molecule Type, 2012 43

Figure 15: Cardiovascular Diseases Market to 2019, Myocardial Infarction, Global, Pipeline by Mechanism of Action, 2012 44

Figure 16: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline, 2012 45

Figure 17: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Molecule Type, 2012 46

Figure 18: Cardiovascular Diseases Market to 2019, Acute Coronary Syndrome, Global, Pipeline by Mechanism of Action, 2012 47

Figure 19: Cardiovascular Diseases Global Market to 2019, Market Size ($m), 2012-2019 53

Figure 20: Cardiovascular Diseases Global Market to 2019, US, Market Size ($m), 2012-2019 55

Figure 21: Cardiovascular Diseases Global Market to 2019, France, Market Size ($m), 2012-2019 57

Figure 22: Cardiovascular Diseases in Global Market to 2019, Spain, Market Size ($m), 2012-2019 59

Figure 23: Cardiovascular Diseases in Global Market to 2019, Germany, Market Size ($m), 2012-2019 61

Figure 24: Cardiovascular Diseases in Global Market to 2019, Italy, Market Size ($m), 2012-2019 63

Figure 25: Cardiovascular Diseases in Global Market to 2019, UK, Market Size ($m), 2012-2019 65

Figure 26: Cardiovascular Diseases in Global Market to 2019, Japan, Market Size ($m), 2012-2019 67

Figure 27: Cardiovascular Diseases in Global Market to 2019, Canada, Market Size ($m), 2012-2019 69

Figure 28: Cardiovascular Diseases Market to 2019, Global, Deals, 2007-2013 72

Figure 29: Cardiovascular Market, Global, Co-development Deals, 2007-2013 73

Figure 30: Cardiovascular Diseases Market to 2019, Global, Licensing Deals, 2007-2013 76

Figure 31: GBI Research Market Forecasting Model 105